Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetravalent Inactivated Enterovirus Vaccine in Children Aged 6 to 71 Months
NCT07611513Phase 3Not yet recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of Tetravalent inactivated enterovirus vaccine in HIV-associated central nervous system involvement (HAND), herpangina, sponsored by Sinovac Biotech Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
Tetravalent inactivated enterovirus vaccine
03
Conditions
HIV-associated central nervous system involvement (HAND)herpangina
Beyond the preview
Go deeper on NCT07611513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07611513.